NOX-A12

NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial With NOX-A12 in Brain Cancer Patients

Retrieved on: 
Friday, January 7, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, ESMO, Clinical trial, Radiation, Safety, MGMT, Pembrolizumab, Brain, Pancreatic cancer, Communication, Patient, Arm, Immune system, PD-1, TME, Tumor microenvironment, NOX-A12, Bevacizumab, GLORIA, CEO, Observation, Merck Sharp & Dohme Federal Credit Union, Neoplasm, Medical device, DSMB, Glioblastoma, Terminology, Data monitoring committee, Pharmaceutical industry, Medical imaging, EU, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

Aram Mangasarian, CEO of NOXXON, commented: "The three arms in the expansion of our Phase 1/2 study of NOX-A12 are supported by the clinical data from the GLORIA trial and are designed to explore the potential for improved benefits for patients with brain tumors.

Key Points: 
  • Aram Mangasarian, CEO of NOXXON, commented: "The three arms in the expansion of our Phase 1/2 study of NOX-A12 are supported by the clinical data from the GLORIA trial and are designed to explore the potential for improved benefits for patients with brain tumors.
  • This is based on our previous observation that NOX-A12 drives infiltration of activated cytotoxic immune cells into brain tumor tissue.
  • We plan to use clinical data from the expansion arms to support our future pivotal glioblastoma study."
  • The GLORIA Phase 1/2 clinical trial evaluates the safety and efficacy of NOX-A12 combined with radiotherapy in newly diagnosed brain cancer (glioblastoma) patients with unmethylated MGMT promoter.

NOXXON Provides Update on Evaluation of NOX-A12 in Non-Oncology Indication by a Leading International Pharma Company

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, MSD, Time, ESMO, Radiation, Safety, MGMT, Pembrolizumab, Brain, Pancreatic cancer, Communication, Patient, OPERA, Immune system, TME, Tumor microenvironment, NOX-A12, GLORIA, CEO, Merck Sharp & Dohme Federal Credit Union, Neoplasm, Merck, Cancer, Merck & Co., Terminology, GBM, Pharmaceutical industry, Medical imaging, EU, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

The pharmaceutical company has decided not to pursue further work with NOX-A12 in this field and to terminate the collaboration agreement.

Key Points: 
  • The pharmaceutical company has decided not to pursue further work with NOX-A12 in this field and to terminate the collaboration agreement.
  • For this trial, NOXXON and MSD (Merck & Co., Inc., Kenilworth, N.J. USA) have entered into their second collaboration.
  • The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments.
  • The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

NOXXON Secures €17 Million Expansion of Equity-Linked Facility with Atlas to Advance NOX-A12 in Glioblastoma and Pancreatic Cancer Programs

Retrieved on: 
Wednesday, December 29, 2021
Safety, Pembrolizumab, ASO, Brain, Stock dilution, Neoplasm, Communication, LLC, Glioblastoma, Immune system, TME, Pancreatic cancer, Terminology, CFO, ESMO, GLORIA, Patient, Tumor microenvironment, Radiation, Merck Sharp & Dohme Federal Credit Union, MGMT, NOX-A12, Pharmaceutical industry, Medical imaging, Annex, EU, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

Additionally, today, NOXXON issued 2,419 convertible bonds (including 44 convertible bonds issued in relation to the transaction fee) for a total of 2.419 million nominal value.

Key Points: 
  • Additionally, today, NOXXON issued 2,419 convertible bonds (including 44 convertible bonds issued in relation to the transaction fee) for a total of 2.419 million nominal value.
  • A total of 17 additional tranches of 1 million nominal value each shall be added to the convertible bond facility upon drawdown by NOXXON of the nominal amount currently available.
  • The total remaining nominal capacity of the vehicle before this expansion and todays issuance stands at 10.45 million.
  • Availability under the amended facility, including the 17 million expansion, is 27.5 million prior to todays issuance.

NOXXON Announces Results of the Extraordinary General Meeting of Shareholders

Retrieved on: 
Wednesday, December 15, 2021
Science, Other Science, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, TME, NOX-A12, Brain, Radiation, GLORIA, Supervisory board, Tumor microenvironment, MGMT, CEO, Proxy, Neoplasm, Safety, Merck Sharp & Dohme Federal Credit Union, Patient, XZ, Immune system, Pembrolizumab, Terminology, ESMO, Pancreatic cancer, Noxxon Pharma, Communication, Medical imaging, Pharmaceutical industry, EU, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

Aram Mangasarian, CEO of NOXXON commented: "I am very pleased that our shareholders agree with the view of NOXXON's management and Supervisory Board that Bryan is the right person to lead the development of the company's financial strategy.

Key Points: 
  • Aram Mangasarian, CEO of NOXXON commented: "I am very pleased that our shareholders agree with the view of NOXXON's management and Supervisory Board that Bryan is the right person to lead the development of the company's financial strategy.
  • Bryan has already begun driving discussions with investors as we increasingly look to raise the company's profile and target further investment, especially in the US."
  • NOXXONs oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair.
  • The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments.

NOXXON to Participate in Banking and Investor Conferences in January and February 2022

Retrieved on: 
Wednesday, December 15, 2021
Biotechnology, Pharmaceutical, Health, Oncology, TME, Chief executive officer, NOX-A12, Direct Corporate Access, Brain, Radiation, GLORIA, Tumor microenvironment, MGMT, BIOMED, Lists of people executed in the United States, CEO, Neoplasm, Safety, Merck Sharp & Dohme Federal Credit Union, Patient, R, CFO, Immune system, Pembrolizumab, Terminology, LSX, ESMO, Congress, Association of British HealthTech Industries, Pancreatic cancer, Technology, Communication, Pharmaceutical industry, Medical imaging, EU, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that Aram Mangasarian, CEO of NOXXON, and Bryan Jennings, CFO of NOXXON, will participate and be available for meetings at several banking and investor conferences in early 2022.

Key Points: 
  • NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that Aram Mangasarian, CEO of NOXXON, and Bryan Jennings, CFO of NOXXON, will participate and be available for meetings at several banking and investor conferences in early 2022.
  • BIOCONNECT hosted by H.C. Wainwright aims to connect life sciences companies with a diverse roster of investors.
  • NOXXONs corporate video presentation will be available on demand from January 10 at 7:00 a.m.
  • The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments.

NOXXON Announces Enrolment of First Patient in the Expansion of the NOX-A12 Phase 1/2 Trial in Brain Cancer

Retrieved on: 
Tuesday, December 7, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Pancreatic cancer, Medical device, Terminology, MGMT, Neoplasm, Bevacizumab, Review, ESMO, Radiation, Immune system, Brain, Safety, Pembrolizumab, Patient, CEO, NOX-A12, GBM, Merck Sharp & Dohme Federal Credit Union, VEGF, Clinical trial, TME, GLORIA, Tumor microenvironment, Glioblastoma, Communication, Pharmaceutical industry, Medical imaging, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

The patient has received their first week of treatment of NOX-A12 (600 mg/week) and the VEGF inhibitor bevacizumab combined with radiotherapy.

Key Points: 
  • The patient has received their first week of treatment of NOX-A12 (600 mg/week) and the VEGF inhibitor bevacizumab combined with radiotherapy.
  • The GLORIA Phase 1/2 clinical trial evaluates the safety and efficacy of NOX-A12 combined with radiotherapy.
  • The expansion arms aim at providing additional clinical data to support the design of the planned pivotal trial and discussions with the regulatory agencies.
  • NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers.

NOXXON Summarizes Essential Points From Key Opinion Leader Event on NOX-A12 & Radiotherapy Combination in Brain Cancer Held on November 23, 2021 With Dr Frank A. Giordano

Retrieved on: 
Thursday, December 2, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Patient, GLORIA, Pakistan Society of Neuro-Oncology, Pancreatic cancer, Safety, Brain, CEO, Temozolomide, Cell, CXCL12, Merck Sharp & Dohme Federal Credit Union, NOX-A12, GBM, Population, MGMT, Cancer, Recurrence, Radiation, Radiation therapy, Tumor microenvironment, Giordano, KOL, NOX, Department, Prognosis, Pembrolizumab, SD, Research, Survival, TME, ESMO, Neoplasm, Communication, Adult, PR, Terminology, SNO, OLA, Society, Immune system, MOS, Disease, University Hospital Bonn, Standard of care, Teaching hospital, Pharmaceutical industry, Medical device, Medical imaging, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

on November 23, 2021, to discuss the combination of NOX-A12 and radiotherapy in brain cancer (glioblastoma, GBM).

Key Points: 
  • on November 23, 2021, to discuss the combination of NOX-A12 and radiotherapy in brain cancer (glioblastoma, GBM).
  • Dr. Giordano is a research pioneer and expert in precision radiation therapy and intraoperative irradiation of malignant tumors.
  • During the KOL event, Dr. Giordano emphasized several other important points, summarized in the Annex to this press release.
  • Key messages from the KOL event on NOX-A12 and radiotherapy combination in brain cancer held on November 23, 2021 with Dr. Frank.

NOXXON: New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in Brain Cancer Presented at the Society for Neuro-Oncology Annual Meeting 2021

Retrieved on: 
Monday, November 22, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Patient, GLORIA, Pakistan Society of Neuro-Oncology, CXCL12, NOX-A12, GBM, MGMT, Radiation, Radiation therapy, Tumor microenvironment, Department, Glioblastoma, Society, TME, SNO, Brain, University Hospital Bonn, Teaching hospital, Medical imaging, Pharmaceutical industry, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

Interestingly and very importantly, such benefits were observed across all available tumor tissue and not only in small subsections.

Key Points: 
  • Interestingly and very importantly, such benefits were observed across all available tumor tissue and not only in small subsections.
  • The data presented by Dr. Giordano at the SNO meeting are a significant step forward in bringing NOX-A12 to glioblastoma patients.
  • NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers.
  • The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments.

NOXXON to Host Key Opinion Leader Webinar on NOX-A12 and Radiotherapy Combination: a Differentiated and Promising New Approach to Treating Brain Cancer

Retrieved on: 
Tuesday, November 16, 2021
Medical Supplies, Biotechnology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Research, Hospitals, Science, Clinical Trials, Society, Safety, University, Brain, SNO, Cancer, Neoplasm, Pakistan Society of Neuro-Oncology, University Hospital Bonn, EST, Glioblastoma, Immune system, Terminology, Department, Teaching hospital, KOL, GBM, TME, Pembrolizumab, Radiation therapy, DKFZ, MGMT, Radiation, ESMO, Standard of care, Tumor microenvironment, GLORIA, Research, American Society for Radiation Oncology, German Cancer Research Center, University Hospital Heidelberg, NCT, Annual general meeting, Peaceful transition of power, CET, Merck Sharp & Dohme Federal Credit Union, National Center of Oncology (Azerbaijan), CXCL12, Communication, Pancreatic cancer, ASTRO, NOX-A12, Patient, Pharmaceutical industry, Medical imaging, Risk management, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

Frank Giordano, M.D., is Director and Chair of the Department of Radiation Oncology at the University Hospital Bonn, Germany.

Key Points: 
  • Frank Giordano, M.D., is Director and Chair of the Department of Radiation Oncology at the University Hospital Bonn, Germany.
  • For many years, his research has focused on optimized radiation therapy of brain cancers to offer cancer patients personalized and even more effective treatment.
  • NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers.
  • The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments.

NOXXON Announces Convocation of an Extraordinary General Meeting of Shareholders

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Safety, Brain, Public health, Person, Director, Neoplasm, Immune system, Terminology, Coronavirus, Writing, Noxxon Pharma, TME, Pembrolizumab, COVID-19, XZ, Radiation, ESMO, Research, Supervisory board, Tumor microenvironment, GLORIA, MGMT, EGM, CET, Merck Sharp & Dohme Federal Credit Union, Proxy, Board of directors, Attendance, Communication, Pancreatic cancer, NOX-A12, Patient, Date, Documentation, Risk management, Security (finance), Medical imaging, Pharmaceutical industry, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

Due to the ongoing coronavirus pandemic this EGM will be convened as a hybrid meeting.

Key Points: 
  • Due to the ongoing coronavirus pandemic this EGM will be convened as a hybrid meeting.
  • Shareholders do not need to be present to cast their vote at the EGM on December 15, 2021.
  • Further details on proxy voting are given in the Attendance Notice for this EGM available on the companys website ( www.noxxon.com ).
  • The company acknowledges that constraints caused by COVID-19 restrict the physical presence of its shareholders at the EGM and thus, to ask questions at the meeting.